REFERENCES
- Wald A, Leisenring W, van Burik J-A, Bowden R AI. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997; 175: 1459–1466, [PUBMED], [INFOTRIEVE], [CSA]
- Coccia-Portugal M A, Sieling W L, Terblanche A P. Aspergillus brain abscess: a case report. S Africa Med J. 1987; 71: 116–118, [CSA]
- Denning D W. Therapeutic outcome in incasive aspergillosis. Clin Infect Dis. 1996; 23: 608–615, [PUBMED], [INFOTRIEVE], [CSA]
- Lin S, Schranz J, Teutsch S. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001; 32: 358–366, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Tattevin P, Bruneel F, Lellouche F. Successful treatment of brain aspergillosis with voriconazole. Clin Microbiol Infect. 2004; 10: 928–931, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ullmann A J. Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr Med Res Opin. 2003; 19: 263–271, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Walsh T J, Karlsson M O, Driscoll T. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother. 2004; 48: 2166–2172, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Jarosova M, Holzerova M, Mihal V. Complex karyotypes in childhood acute lymphoblastic leukemia: cytogenetic and molecular cytogenetic study of 21 cases. Cancer Genet Cytogenet. 2003; 145: 161–168, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Schrappe M, Reiter A, Ludwig W D. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000; 95: 3310–3322, [PUBMED], [INFOTRIEVE], [CSA]
- Ng A, Gadong N, Kelsey A, Denning D W, Leggate J, Eden O B. Successful treatment of aspergillus brain abscess in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2000; 17: 497–504, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Denning D W, Stevens D A. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev Infect Dis. 1990; 12: 1147–1182, [PUBMED], [INFOTRIEVE], [CSA]
- Abbasi S, Shenep J L, Hughes W T. Aspergillosis in children with cancer: a 34-year experience. Clin Infect Dis. 1999; 29: 1210–1219, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Herbrecht R, Denning D W, Patterson T F. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002; 347: 408–415, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Walsh T J, Pappas P, Winston D J. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002; 346: 225–234, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Schwartz S, Thiel E. Update on the treatment of cerebral aspergillosis. Ann Hematol. 2004; 83: S42–S44, Suppl 1[PUBMED], [INFOTRIEVE], [CSA]
- Chan J D. Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports. Pharmacotherapy. 1998; 18: 1304–1307, [PUBMED], [INFOTRIEVE], [CSA]
- Bowden R, Chandresekar P, White M H. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive Aspergillosis in immmunocompromised patients. Clin Infect Dis. 2002; 35: 359–364, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Clemons K V, Stevens D A. Comparative efficacies of four amphotericin B formulations—Fungizone, Amphotec (Amphocil), AmBisome, and Abelcet—against systemic murine aspergillosis. Antimicrob Agents Chemother. 2004; 48: 1047–1050, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Grasso G, Sfacteria A, Cerami A, Brines M. Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go?. Neuroscientist. 2004; 10: 93–98, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]